截至目前，人类对罗伊氏乳杆菌的研究还没有出现有关不良事件的报道。
There have been no reports of adverse events so far in human Lactobacillus reuteri studies.
在一些流行地区和接受疫苗接种的旅行者(例如，在巴西、澳大利亚、美国、秘鲁和多哥)中，在免疫接种后出现严重不良事件的报告并不多见。
Serious adverse events have been reported rarely following immunization in a few endemic areas and among vaccinated travelers (e.g. in Brazil, Australia, the United States, Peru and Togo).
为了尽可能地降低接受双氯芬酸治疗的患者出现肝脏相关不良事件的潜在风险，应采用最小有效剂量，并尽量缩短用药时间。
To minimize the potential risk for an adverse liver-related event in patients treated with diclofenac, the lowest effective dose should be used for the shortest duration possible.
应用推荐